ACXP

Acurx Pharmaceuticals LLC · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website acurxpharma.com
Employees(FY) 4
ISIN US00510M1045

Performance

-24.86%

-30.85%

-34.43%

-38.22%

-63.71%

YTD

-61.6%

Profile

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. It is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. The company was incorporated in 2017 and is headquartered in Staten Island, New York.

Advanced Technical Analysis

Technical Analysis of ACXP 2024-11-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 3 and the Technical Score at 21, both indicating weak performance. The Oscillators Score of 40 suggests a neutral stance, but overall, the combined scores point to a lack of bullish momentum in the market.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ACXP

Stock Rank

Recent News & Updates

2024-11-19 18:01
Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset(Prnewswire)
2024-11-17 18:00
Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update(Prnewswire)
2024-11-17 18:00
Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update(Yahoo Finance)
2024-11-13 13:07
Acurx Pharmaceuticals Inc (ACXP) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...(Yahoo Finance)
2024-11-12 18:00
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update(Prnewswire)
2024-10-31 03:00
New to The Street to Air as Sponsored Programming on Bloomberg Friday, November 1st, Featuring Modular Medical, OriginClear With Shark Tank's Kevin Harrington, Acurx Pharmaceuticals, the Sustainable Green Team, and SEKURs "Hack of the Week"(Yahoo Finance)
2024-10-27 22:00
New to The Street on Fox Business Premieres Exclusive Sponsored Programming Tonight Featuring Modular Medical (NASDAQ:MODD), Acurx Pharmaceuticals (NASDAQ:ACXP), and LightPath Technologies (NASDAQ:LPTH)(Accesswire)
2024-10-20 19:00
Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference(Prnewswire)
2024-10-16 20:00
Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement(Prnewswire)
2024-10-15 20:00
Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024(Prnewswire)
2024-10-14 01:00
New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support(Accesswire)
2024-10-10 23:05
New to the Street Announces Exclusive Bloomberg Lineup for Saturday October 12 at 6:30 PM EST(Accesswire)
2024-10-10 22:50
New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST(Accesswire)
2024-09-25 19:00
Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues(Prnewswire)
2024-09-23 19:00
Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium(Prnewswire)
2024-09-08 20:30
New to the Street Announces Its Five Corporate Interviews, Airing Episode 599 on the Fox Business Network, Tonight Monday, September 9, 2024, at 10:30 PM PT September 9, 2024 09:15 ET(Yahoo Finance)
2024-08-25 21:15
New to The Street Announces its Five Corporate Interviews, Airing Episode 591 on the Fox Business Network, Tonight Monday, August 26, 2024, at 10:30 PM PT(Globenewswire)
2024-08-25 19:00
ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference(Prnewswire)
2024-08-18 21:20
New to The Street Announces Episode 590, Five Corporate Interviews, Airing on the Fox Business Network, Tonight Monday, August 19, 2024, at 10:30 PM PT(Globenewswire)
2024-08-09 20:18
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q2 2024 Earnings Call Transcript(Insidermonkey)
2024-08-08 21:30
New to The Street TV Announces Episode 583, Five Riveting Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Saturday, August 10, 2024, at 6:30 PM ET(Globenewswire)
2024-08-08 19:01
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update(Prnewswire)
2024-07-16 19:00
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome(Prnewswire)
2024-07-15 19:00
Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update(Prnewswire)
2024-07-14 19:00
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference(Prnewswire)
2024-06-05 21:30
New to The Street Announces Episode 576, Four Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, Thursday, June 6, 2024, at 9:30 PM PT(Globenewswire)
2024-05-15 15:00
Acurx Pharmaceuticals Inc (ACXP) Q1 2024 Earnings Call Transcript Highlights: Key Financial and ...(Yahoo Finance)
2024-05-15 10:40
Q1 2024 Acurx Pharmaceuticals Inc Earnings Call(Yahoo Finance)
2024-05-14 21:53
ACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q1 2024(Investorplace)
2024-05-14 21:00
Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection(Prnewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.